USPTO Upholds Patentability of Genetic Technologies' IP | GenomeWeb

NEW YORK (GenomeWeb News) – Genetic Technologies announced today it received a further ex parte re-examination certificate from the US Patent and Trademark Office for certain claims related to the company's non-coding DNA patent.

The Australian firm said that the certificate follows the third request for ex parte re-examination by Duluth, Ga.-based Merial of claims 1-15, 17, 18, 26-29, and 32 of US Patent No. 5,612,179. In the certificate, the USPTO confirms the patentability of all the claims, and no amendments were made to the '179 patent, GTG said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.